$GSK — ADD 📊 | 6 MONTHS THESIS

$GSK — ADD 📊 | 6 MONTHS THESIS 🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢 💡 Consensus expected earnings to be pressured by generic competition and Zantac liability, but the beat indicates core franchises are resilient and cost controls are effective. The market is discounting litigation worst-case scenarios, whereas we see a higher probability of manageable outcomes and estimate upgrades. 📉 Reward/risk: 2.3:1 🏢 Business Quality: 7/10 - Diversified pharma with strong vaccines and specialty portfolio, solid ROIC (~20%), but faces patent cliffs and Zantac litigation overhang that introduce uncertainty. 📊 Valuation: cheap — Triangulated via: (1) P/E: trailing 12.5x vs 5‑yr avg 14x and peer group 15x; (2) FCF yield: ~7% vs peers 5%; (3) reverse DCF implies -1%... 📊 Our read: ADD. Full analysis → https://stockduty.xyz/s/GSK0614

🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢